Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis
20 juin 2019 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference
17 juin 2019 08h30 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Announces $10 Million Registered Direct Offering of Common Stock
13 juin 2019 08h00 HE
|
Spero Therapeutics, Inc.
Novo Holdings A/S through its Novo REPAIR Impact Fund to Invest Up to $10 million Net Proceeds to Advance Spero’s SPR720 CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics,...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 mai 2019 17h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review
09 mai 2019 16h10 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 mai 2019 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
08 avr. 2019 08h30 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis
29 mars 2019 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Announces Appointment of Cynthia Smith to its Board of Directors
19 mars 2019 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present at March Investor Conferences
01 mars 2019 08h30 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...